Fullcro
Fullcro is recorded as a service provider in 12 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 12 of 12 trials · Latest update first
AGNOSTIC THERAPY IN A PHASE II, MULTICENTER, SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB (MEDI 4736) IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA (EPSCC) – DURVASCC TRIAL
Sponsor GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized, run-in, phase II study of nivolumab combined with ipilimumab and oral decitabine/cedazuridine (ASTX727) or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/PD-L1
Sponsor Fondazione NIBIT Onlus
- Start (EU)
- Latest update
- Estimated end
- Not reported
MITO 25.1: A randomized, molecular driven phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib, selected according to HRD status, in patients with advanced (stage IIIB-C-IV) ovarian, primary peritoneal and Fallopian tube cancer preceded by a phase I dose escalation study on Rucaparib-Bevacizumab combination
Sponsor Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Start (EU)
- Latest update
- Estimated end
- Not reported
A phase 2, multicentric study to assess the efficacy and safety of maribavir treatment in hematopoietic stem cell transplant (HSCT) recipients with cytomegalovirus (CMV) infection with a medical condition that contraindicate the administration of ganciclovir, valganciclovir or foscarnet and in those who discontinued first line preemptive therapy with ganciclovir, valganciclovir or foscarnet due to toxicity or intolerance.
Sponsor Gruppo Italiano Per Il Trapianto Di Midollo Osseo Cellule Staminali Emopoietiche E Terapia Cellulare
- Start (EU)
- Latest update
- Estimated end
- Not reported
A double-blind, randomized, placebo-controlled trial to test the efficacy, safety and tolerability of Dimethyl Fumarate in Friedreich Ataxia (DMF-FA-201).
Sponsor Dipartimento Di Neuroscienze E Scienze Riproduttive Ed Odontostomatologiche Universita Degli Studi Di Napoli Federico II
- Start (EU)
- Latest update
- Estimated end
- Not reported
Inhibition of late sodium current (INa) to prevent coronary MICROvascular dysfunction in patients presenting with ST-Elevation myocardial infarction and multivessel disease: A multicenter, randomized, controlled and open label study (INaMICRON study)
Sponsor Universita' Degli Studi Di Napoli Federico II
- Start (EU)
- Latest update
- Estimated end
- Not reported
SURE-02_An open label, single-arm, phase 2 study of perioperative pembrolizumab plus sacituzumab govitecan, and bladder-saving approach, for patients with muscle-invasive bladder cancer who cannot receive or refuse cisplatin-based chemotherapy
Sponsor Ospedale San Raffaele S.r.l.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Efficacy and safety of Silycus® in Cushing’s disease: a multicenter, single arm, open label, dose titration, proof of concept study (Silycus®-21)
Sponsor Istituto Biochimico Italiano Giovanni Lorenzini S.p.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase II randomized trial of XELOX plus DoSTARlimab versus XELOX alone as Consolidation Treatment after Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients – IMMUNOSTAR Trial - GOIRC-02-2024
Sponsor G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica
- Start (EU)
- Latest update
- Estimated end
- Not reported
Impact of GLP1-RAs on inflammation and endothelial biomarkerS in Type 2 diABetes meLlitus patiEnts: STABLE-GLP1 trial.
Sponsor Universita' Degli Studi Di Napoli Federico II
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
MITO CERV4: Single arm phase II study on Pembrolizumab in pre neoplastic high grade HPV-related vulvar and cervical lesions
Sponsor Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Effect of metyrapone on cardiovascular risk factors in patients with adrenal incidentalomas and subclinical/mild Cushing's syndrome
Sponsor Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Fullcro?
The 2026-10-09 snapshot links Fullcro to 12 distinct CTIS trials. Recorded services include Regulatory services, Clinical monitoring, Data management, Project management, among 14 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Fullcro?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Dermatology, Gynecology, Respiratory. Recorded phases include Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Fullcro conducted?
The linked trials record locations in 1 country, including Italy. These are trial locations, not confirmed office locations or countries where Fullcro delivered services.
What can this page tell me about Fullcro's trial experience?
Browse 12 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Fullcro. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Fullcro S.r.l.